RYTM - Rhythm Pharmaceuticals Inc Stock Price, Fair Value and News

38.92USD-0.43 (-1.09%)Market Closed

Market Summary

USD38.92-0.43

Market Closed

-1.09%

RYTM Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

RYTM Stock Price

View Fullscreen

RYTM RSI Chart

RYTM Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-8.66

Price/Sales (Trailing)

25.81

EV/EBITDA

-8.83

Price/Free Cashflow

-16.89

RYTM Price/Sales (Trailing)

RYTM Profitability

EBT Margin

-302.94%

Return on Equity

-444.73%

Return on Assets

-105.88%

Free Cashflow Yield

-5.92%

RYTM Fundamentals

RYTM Revenue

Revenue (TTM)

91.9M

Rev. Growth (Yr)

126.41%

Rev. Growth (Qtr)

7.15%

RYTM Earnings

Earnings (TTM)

-273.9M

Earnings Growth (Yr)

-170.94%

Earnings Growth (Qtr)

-239.57%

Breaking Down RYTM Revenue

Last 7 days

-6.1%

Last 30 days

-6.9%

Last 90 days

-18.1%

Trailing 12 Months

127.5%

How does RYTM drawdown profile look like?

RYTM Financial Health

Current Ratio

4.35

Debt/Equity

1.18

Debt/Cashflow

-1.93

RYTM Investor Care

Shares Dilution (1Y)

7.24%

Diluted EPS (TTM)

-3.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	91.9M	0	0	0
2023	33.6M	43.8M	62.0M	77.4M
2022	8.3M	13.4M	18.5M	23.6M
2021	0	0	0	3.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rhythm Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 14, 2024	mazabraud yann	sold	-	-	-10,375	evp, head of international
Apr 02, 2024	german christopher paul	sold	-15,367	41.76	-368	corporate controller & cao
Mar 21, 2024	shulman joseph	sold	-735,600	40.34	-18,235	chief technical officer
Mar 20, 2024	german christopher paul	acquired	-	-	1,163	corporate controller & cao
Mar 20, 2024	lee jennifer kayden	sold	-707,005	38.7719	-18,235	evp, head of north america
Mar 19, 2024	shulman joseph	sold	-608,498	39.22	-15,515	chief technical officer
Mar 19, 2024	smith hunter c	sold	-608,498	39.22	-15,515	chief financial officer
Mar 19, 2024	mazabraud yann	sold	-627,520	39.22	-16,000	evp, head of international
Mar 19, 2024	cramer pamela j.	sold	-608,498	39.22	-15,515	chief human resources officer
Mar 19, 2024	meeker david p	sold	-1,784,270	39.22	-45,494	president and ceo

Which funds bought or sold RYTM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Arizona State Retirement System	added	2.1	-22,027	562,987	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	220	2,992,250	4,473,950	-%
May 07, 2024	Swiss National Bank	added	4.01	-80,820	4,042,690	-%
May 07, 2024	Concurrent Investment Advisors, LLC	sold off	-100	-343,488	-	-%
May 07, 2024	SEI INVESTMENTS CO	added	85.78	213,176	496,991	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-0.19	-89,000	1,422,000	-%
May 06, 2024	SG Americas Securities, LLC	added	0.17	-19,000	326,000	-%
May 06, 2024	Parallel Advisors, LLC	unchanged	-	-13.00	217	-%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-0.12	-28,000	456,000	-%
May 06, 2024	Jefferies Financial Group Inc.	reduced	-33.64	937,438	3,772,340	0.03%

Are Funds Buying or Selling RYTM?

Are funds buying RYTM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RYTM

No. of Funds

Unveiling Rhythm Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 30, 2024	new enterprise associates 13 lp	-	0	SC 13D/A
Apr 17, 2024	perceptive advisors llc	8.3%	5,143,575	SC 13D/A
Apr 03, 2024	perceptive advisors llc	5.4%	3,268,579	SC 13D/A
Mar 20, 2024	perceptive advisors llc	5.4%	3,268,579	SC 13D
Feb 14, 2024	ra capital management, l.p.	9.0%	5,330,412	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	10.8%	6,398,365	SC 13G/A
Feb 13, 2024	vanguard group inc	5.46%	3,226,938	SC 13G
Feb 12, 2024	primecap management co/ca/	13.63%	8,052,648	SC 13G/A
Feb 12, 2024	perceptive advisors llc	5.5%	3,260,013	SC 13G
Feb 05, 2024	goldman sachs group inc	8.5%	4,998,761	SC 13G/A

Recent SEC filings of Rhythm Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 30, 2024	SC 13D/A	13D - Major Acquisition
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Rhythm Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Rhythm Pharmaceuticals Inc News

Latest updates

Rhythm Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	7.2%	25,967,000	24,234,000	22,504,000	19,221,000	11,469,000	8,790,000	4,284,000	9,066,000	1,498,000	-	-	-	-
Costs and Expenses	153.2%	165,854,000	65,501,000	66,457,000	65,825,000	64,000,000	50,893,000	43,551,000	54,162,000	54,189,000	52,806,000	45,268,000	40,706,000	34,433,000
S&GA Expenses	6.2%	34,382,000	32,375,500	30,475,000	30,046,000	24,634,000	26,317,000	21,938,000	22,328,000	21,449,000	20,996,000	17,507,000	15,465,000	14,518,000
R&D Expenses	330.4%	128,665,000	29,892,500	33,570,000	33,543,000	37,945,000	23,548,000	21,116,000	31,456,000	32,510,000	31,574,000	27,539,000	25,104,000	19,911,000
EBITDA Margin	-33.7%	-2.85	-2.13	-2.79	-4.00	-5.20	-7.40	-	-	-	-	-	-	-
Interest Expenses	6.5%	4,755,000	4,464,500	3,149,000	3,303,000	3,061,000	-	2,144,000	46,000	-	-	-	-	-
Income Taxes	53.1%	300,000	196,000	368,000	-	-	-	-	-	-	-	-8,995,000	-5,022,000	22,006,000
Earnings Before Taxes	-240.4%	-141,072,000	-41,437,000	-43,795,000	-	-52,179,000	-42,493,000	-40,861,000	-	-	-63,840,000	-	-40,411,000	65,756,000
EBT Margin	-30.4%	-3.03	-2.32	-2.89	-4.14	-5.39	-7.66	-3.76	-5.20	-8.41	-22.07	-	-	-
Net Income	-239.6%	-141,372,000	-41,633,000	-44,163,000	-46,703,000	-52,179,000	-42,493,000	-40,861,000	-45,001,000	-52,764,000	-42,866,000	-35,107,000	-35,389,000	43,750,000
Net Income Margin	-24.9%	-2.98	-2.39	-2.99	-4.16	-5.37	-7.66	-9.80	-13.12	-20.08	-22.07	-	-	-
Free Cashflow	-38.7%	-40,742,000	-29,382,000	-29,252,000	-41,090,000	-36,480,000	-33,999,000	-47,082,000	-38,869,000	-53,759,000	-40,540,000	-40,266,000	-32,088,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-22.3%	259	333	354	310	346	382	390	278	285	330	356	388	422	187	215	243	274	309	178	211	237
Current Assets	-23.5%	236	308	329	284	318	354	362	249	253	308	336	378	412	182	210	238	268	302	171	204	230
Cash Equivalents	-11.1%	53.00	60.00	65.00	116	110	128	185	113	79.00	59.00	92.00	69.00	87.00	101	68.00	59.00	56.00	63.00	72.00	64.00	42.00
Inventory	-1.4%	9.00	9.00	8.00	6.00	5.00	3.00	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-14.3%	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	3.00
Liabilities	20.9%	197	163	157	128	126	118	108	82.00	49.00	45.00	34.00	37.00	41.00	21.00	19.00	18.00	21.00	28.00	28.00	29.00	16.00
Current Liabilities	-1.9%	54.00	55.00	50.00	46.00	46.00	40.00	33.00	45.00	47.00	43.00	23.00	17.00	17.00	18.00	16.00	15.00	18.00	24.00	25.00	26.00	13.00
Long Term Debt	-	-	-	-	-	-	-	73.00	34.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-63.7%	62.00	170	197	182	220	264	281	196	236	284	322	352	381	167	197	226	253	281	149	181	220
Retained Earnings	-15.8%	-1,036	-894	-853	-808	-762	-710	-667	-626	-581	-528	-486	-450	-415	-459	-424	-390	-359	-325	-292	-256	-213
Additional Paid-In Capital	3.1%	1,098	1,064	1,051	991	982	974	949	823	818	813	808	803	797	626	621	616	613	606	441	438	434
Shares Outstanding	2.6%	61.00	59.00	59.00	57.00	57.00	57.00	51.00	50.00	50.00	50.00	49.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	887	-	-	-	188	-	-	-	884	-	-	-	828	-	-	-	569	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-38.7%	-40,743	-29,383	-29,251	-41,090	-36,433	-34,000	-46,987	-38,809	-53,632	-40,472	-40,160	-31,840	-33,531	-29,122	-27,031	-29,729	-36,098	-32,221	-33,605	-25,546	-31,378
Share Based Compensation	-10.5%	7,767	8,674	8,612	8,891	6,376	5,287	4,796	5,137	4,611	4,676	5,268	5,669	5,191	4,257	4,695	3,028	5,475	2,924	3,035	3,272	2,644
Cashflow From Investing	32.7%	30,050	22,640	-94,960	48,191	18,464	-40,775	-39,697	35,979	72,522	7,248	62,780	13,525	-145,712	61,887	34,910	32,861	28,873	-139,127	41,471	46,145	23,541
Cashflow From Financing	75.1%	4,243	2,423	73,043	-965	-133	17,365	158,564	37,500	399	100	413	383	165,585	420	699	183	707	161,963	697	498	316

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RYTM Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 25,967	$ 11,469
Costs and expenses:
Cost of sales	2,807	1,421
Research and development	128,665	37,945
Selling, general, and administrative	34,382	24,634
Total costs and expenses	165,854	64,000
Loss from operations	(139,887)	(52,531)
Other (expense) income:
Other income (expense), net	524	(27)
Interest expense	(4,755)	(3,061)
Interest income	3,046	3,440
Total other (expense) income, net	(1,185)	352
Loss before taxes	(141,072)	(52,179)
Provision for income taxes	300
Net loss	$ (141,372)	$ (52,179)
Net loss per share, basic (in dollars per share)	$ (2.35)	$ (0.92)
Weighted-average common shares outstanding, basic (in shares)	60,143,558	56,708,975
Other comprehensive loss:
Net Income (Loss)	$ (141,372)	$ (52,179)
Foreign currency translation adjustment	(71)	21
Unrealized gain (loss), net on marketable securities	(244)	65
Comprehensive loss	(141,687)	(52,093)
Product revenue
Total revenues	$ 25,967	$ 11,469

RYTM Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 53,428	$ 60,081
Short-term investments	147,771	215,765
Accounts receivable, net	14,695	14,867
Inventory	8,507	8,624
Prepaid expenses and other current assets	11,352	8,931
Total current assets	235,753	308,268
Property and equipment, net	1,149	1,341
Right-of-use asset	670	781
Intangible assets, net	6,815	7,028
Restricted cash	460	328
Other long-term assets	13,804	14,999
Total assets	258,651	332,745
Current liabilities:
Accounts payable	7,550	4,885
Accrued expenses and other current liabilities	44,531	48,262
Deferred revenue	1,286	1,286
Lease liability	793	770
Total current liabilities	54,160	55,203
Long-term liabilities:
Deferred royalty obligation	107,368	106,143
Lease liability, non-current	284	490
Derivative liability	660	1,150
Other long-term liabilities	34,598
Total liabilities	197,070	162,986
Stockholders' equity:
Common stock, $0.001 par value: 120,000,000 shares authorized; 59,426,559 and 56,612,429 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	60	59
Additional paid-in capital	1,097,810	1,064,302
Accumulated other comprehensive income (loss)	(181)	134
Accumulated deficit	(1,036,108)	(894,736)
Total stockholders' equity	61,581	169,759
Total liabilities and stockholders' equity	$ 258,651	$ 332,745

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and AlstrÃƒÂ¶m syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO	Dr. David P. Meeker M.D.
WEBSITE	https://rhythmtx.com
INDUSTRY	Biotechnology
EMPLOYEES	177

Rhythm Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rhythm Pharmaceuticals Inc? What does RYTM stand for in stocks?

RYTM is the stock ticker symbol of Rhythm Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rhythm Pharmaceuticals Inc (RYTM)?

As of Wed May 08 2024, market cap of Rhythm Pharmaceuticals Inc is 2.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RYTM stock?

You can check RYTM's fair value in chart for subscribers.

What is the fair value of RYTM stock?

You can check RYTM's fair value in chart for subscribers. The fair value of Rhythm Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rhythm Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RYTM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rhythm Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RYTM is over valued or under valued. Whether Rhythm Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rhythm Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RYTM.

What is Rhythm Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, RYTM's PE ratio (Price to Earnings) is -8.66 and Price to Sales (PS) ratio is 25.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RYTM PE ratio will change depending on the future growth rate expectations of investors.